Skip to main content
BJR alerts
Full paper

Role of imaging techniques in the diagnosis of dementia

Published Online:https://doi.org/10.1259/bjr/33117326

Abstract

Dementia is a common and growing problem, affecting 5% of the over 65s and 20% of the over 80s. The recent availability of new treatments for dementia, as well as the importance of subtype-specific management, has renewed interest in the use of brain imaging techniques that can assist in the accurate recognition of Alzheimer's disease (AD), dementia with Lewy bodies (DLB), vascular dementia (VaD) and frontotemporal dementia (FTD). Structural imaging, historically used to exclude an intracerebral lesion as a cause for dementia, is increasingly playing a role in “ruling in” diagnoses, with atrophy of the hippocampus and entorhinal cortex an early and sensitive marker for AD, and cortical and subcortical infarcts and white matter lesions characteristic of VaD. Regionally distinct patterns of hypoperfusion on single-photon emission computed tomography (SPECT) or hypometabolism on positron emission tomography (PET) can help differentiate FTD, AD and VaD, and dopaminergic loss in the basal ganglia can differentiate DLB from AD. Newer techniques show great promise to detect specific neuroreceptor changes as well as pathological underpinnings of dementia, such as amyloid and tau pathology.

References

  • 1 McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939–44. Crossref Medline ISIGoogle Scholar

  • 2 Roman GC, Tatemichi TK, Erkinjuntti T, Cummings JL, Masdeu JC, Garcia JH, et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop [see comments]. Neurology 1993;43:250–60. Crossref Medline ISIGoogle Scholar

  • 3 McKeith IG, Dickson DW, Lowe J, Emre M, O'Brien JT, Feldman H, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005;65:1863–72. Crossref Medline ISIGoogle Scholar

  • 4 McKhann GM, Albert MS, Grossman M, Miller B, Dickson D, Trojanowski JQ, et al. Clinical and pathological diagnosis of frontotemporal dementia: report of the Work Group on Frontotemporal Dementia and Pick's Disease [see comment]. Arch Neurol 2001;58:1803–9. Crossref MedlineGoogle Scholar

  • 5 Neary D, Snowden JS, Gustafson L, Passant U, Stuss D, Black S, et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria [see comment]. Neurology 1998;51:1546–54. Crossref Medline ISIGoogle Scholar

  • 6 Gold G, Bouras C, Canuto A, Bergallo MF, Herrmann FR, Hof PR, et al. Clinicopathological validation study of four sets of clinical criteria for vascular dementia. Am J Psychiatry 2002;159:82–7. Crossref Medline ISIGoogle Scholar

  • 7 Litvan I, Bhatia KP, Burn DJ, Goetz CG, Lang AE, McKeith I, et al. Movement Disorders Society Scientific Issues Committee report: SIC Task Force appraisal of clinical diagnostic criteria for Parkinsonian disorders. Mov Disord 2003;18:467–86. Crossref Medline ISIGoogle Scholar

  • 8 Clarfield AM. The decreasing prevalence of reversible dementias: an updated meta-analysis. Arch Intern Med 2003;163:2219–29. Crossref MedlineGoogle Scholar

  • 9 Jobst KA, Smith AD, Szatmari M, Molyneux A, Esiri ME, King E, et al. Detection in life of confirmed Alzheimer's disease using a simple measurement of medial temporal lobe atrophy by computed tomography. Lancet 1992;340:1179–83. Crossref Medline ISIGoogle Scholar

  • 10 O'Brien JT, Metcalfe S, Swann A, Hobson J, Jobst K, Ballard C, et al. Medial temporal lobe width on CT scanning in Alzheimer's disease: comparison with vascular dementia, depression and dementia with Lewy bodies. Dement Geriatr Cogn Disord 2000;11:114–18. Crossref Medline ISIGoogle Scholar

  • 11 Scheltens P, Fox N, Barkhof F, De Carli C. Structural magnetic resonance imaging in the practical assessment of dementia: beyond exclusion. Lancet Neurol 2002;1:13–21. Crossref Medline ISIGoogle Scholar

  • 12 Du AT, Schuff N, Amend D, Laakso MP, Hsu YY, Jagust WJ, et al. Magnetic resonance imaging of the entorhinal cortex and hippocampus in mild cognitive impairment and Alzheimer's disease. J Neurol Neurosurg Psychiatry 2001;71:441–7. Crossref Medline ISIGoogle Scholar

  • 13 Scheltens P, Launer LJ, Barkhof F, Weinstein HC, van Gool WA. Visual assessment of medial temporal lobe atrophy on magnetic resonance imaging: interobserver reliability. J Neurol 1995;242:557–60. Crossref Medline ISIGoogle Scholar

  • 14 Barber R, Gholkar A, Scheltens P, Ballard C, McKeith IG, O'Brien JT. Medial temporal lobe atrophy on MRI in dementia with Lewy bodies. Neurology 1999;52:1153–8. Crossref Medline ISIGoogle Scholar

  • 15 de Leon MJ, DeSanti S, Zinkowski R, Mehta PD, Pratico D, Segal S, et al. MRI and CSF studies in the early diagnosis of Alzheimer's disease. J Intern Med 2004;256:205–23. Crossref Medline ISIGoogle Scholar

  • 16 Jack CR, Jr., Dickson DW, Parisi JE, Xu YC, Cha RH, O'Brien PC, et al. Antemortem MRI findings correlate with hippocampal neuropathology in typical aging and dementia. Neurology 2002;58:750–7. Crossref Medline ISIGoogle Scholar

  • 17 Scahill RI, Schott JM, Stevens JM, Rossor MN, Fox NC. Mapping the evolution of regional atrophy in Alzheimer's disease: unbiased analysis of fluid-registered serial MRI. Proc Natl Acad Sci USA 2002;99:4703–7. Crossref Medline ISIGoogle Scholar

  • 18 Burton EJ, McKeith IG, Burn DJ, Williams ED, O' Brien JT. Cerebral atrophy in Parkinson's disease with and without dementia: a comparison with Alzheimer's disease, dementia with Lewy bodies and controls. Brain 2004;127:791–800. Crossref Medline ISIGoogle Scholar

  • 19 Burton EJ, Karas G, Paling SM, Barber R, Williams ED, Ballard CG, et al. Patterns of cerebral atrophy in dementia with Lewy bodies using voxel-based morphometry. Neuroimage 2002;17:618–30. Crossref Medline ISIGoogle Scholar

  • 20 Whitwell JL, Weigand SD, Shiung MM, Boeve BF, Ferman TJ, Smith GE, et al. Focal atrophy in dementia with Lewy bodies on MRI: a distinct pattern from Alzheimer's disease. Brain 2007;130:708–19. Crossref Medline ISIGoogle Scholar

  • 21 Barber R, Gholkar A, Scheltens P, Ballard C, McKeith IG, Morris CM, et al. Apolipoprotein E epsilon4 allele, temporal lobe atrophy, and white matter lesions in late-life dementias. Arch Neurol 1999;56:961–5. Crossref MedlineGoogle Scholar

  • 22 Wahlund L-O, Almkvist O, Blennow K, Engedahl K, Johansson A, Waldemar G, et al. Evidence-based evaluation of magnetic resonance imaging as a diagnostic tool in dementia workup. Top Magn Reson Imaging 2005;16:427–37. Crossref MedlineGoogle Scholar

  • 23 Fox NC, Freeborough PA, Rossor MN. Visualisation and quantification of rates of atrophy in Alzheimer's disease [see comment]. Lancet 1996;348:94–7. Crossref Medline ISIGoogle Scholar

  • 24 O'Brien JT, Paling S, Barber R, Williams ED, Ballard C, McKeith IG, et al. Progressive brain atrophy on serial MRI in dementia with Lewy bodies, AD, and vascular dementia. Neurology 2001;56:1386–8. Crossref Medline ISIGoogle Scholar

  • 25 Ridha BH, Barnes J, Bartlett JW, Godbolt A, Pepple T, Rossor MN, et al. Tracking atrophy progression in familial Alzheimer's disease: a serial MRI study [see comment]. Lancet Neurol 2006;5:828–34. Crossref Medline ISIGoogle Scholar

  • 26 Fox NC, Cousens S, Scahill R, Harvey RJ, Rossor MN. Using serial registered brain magnetic resonance imaging to measure disease progression in Alzheimer disease: power calculations and estimates of sample size to detect treatment effects [see comments]. Arch Neurol 2000;57:339–44. Crossref MedlineGoogle Scholar

  • 27 Hashimoto M, Kazui H, Matsumoto K, Nakano Y, Yasuda M, Mori E. Does donepezil treatment slow the progression of hippocampal atrophy in patients with Alzheimer's disease? [see comment]. Am J Psychiatry 2005;162:676–82. Crossref Medline ISIGoogle Scholar

  • 28 Fox NC, Black RS, Gilman S, Rossor MN, Griffith SG, Jenkins L, et al. Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology 2005;64:1563–72. Crossref Medline ISIGoogle Scholar

  • 29 Archer HA, Edison P, Brooks DJ, Barnes J, Frost C, Yeatman T, et al. Amyloid load and cerebral atrophy in Alzheimer's disease: an 11C-PIB positron emission tomography study. Ann Neurol 2006;60:145–7. Crossref Medline ISIGoogle Scholar

  • 30 den Heijer T, Geerlings MI, Hoebeek FE, Hofman A, Koudstaal PJ, Breteler MMB. Use of hippocampal and amygdalar volumes on magnetic resonance imaging to predict dementia in cognitively intact elderly people. Arch Gen Psychiatry 2006;63:57–62. Crossref MedlineGoogle Scholar

  • 31 Kantarci K, Petersen RC, Boeve BF, Knopman DS, Weigand SD, O'Brien PC, et al. DWI predicts future progression to Alzheimer disease in amnestic mild cognitive impairment. Neurology 2005;64:902–4. Crossref Medline ISIGoogle Scholar

  • 32 de Leon MJ, Mosconi L, Blennow K, DeSanti S, Zinkowski R, Mehta PD, et al. Imaging and CSF studies in the preclinical diagnosis of Alzheimer's disease. Ann N Y Acad Sci 2007;1097:114–45. Crossref Medline ISIGoogle Scholar

  • 33 Pakrasi S, O'Brien JT. Emission tomography in dementia. Nucl Med Commun 2005;26:189–96. Crossref Medline ISIGoogle Scholar

  • 34 Dougall NJ, Bruggink S, Ebmeier KP. Systematic review of the diagnostic accuracy of 99mTc-HMPAO-SPECT in dementia. Am J Geriatr Psychiatry 2004;12:554–70. Crossref Medline ISIGoogle Scholar

  • 35 Bonte FJ, Harris TS, Hynan LS, Bigio EH, White CL, 3rd. Tc-99m HMPAO SPECT in the differential diagnosis of the dementias with histopathologic confirmation. Clin Nucl Med 2006;31:376–8. Crossref Medline ISIGoogle Scholar

  • 36 Silverman DH, Small GW, Chang CY, Lu CS, Kung De Aburto MA, Chen W, et al. Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome. J Am Med Assoc 2001;286:2120–7. Crossref ISIGoogle Scholar

  • 37 Jagust W, Thisted R, Devous MD, Sr., Van Heertum R, Mayberg H, Jobst K, et al. SPECT perfusion imaging in the diagnosis of Alzheimer's disease: a clinical-pathologic study. Neurology 2001;56:950–6. Crossref Medline ISIGoogle Scholar

  • 38 O'Brien JT, Colloby SJ, Pakrasi S, Perry EK, Pimlott SL, Wyper DJ, et al. Alpha4beta2 nicotinic receptor status in Alzheimer's disease using 123I-5IA-85380 single-photon-emission computed tomography. J Neurol Neurosurg Psychiatry 2007;78:356–62. Crossref Medline ISIGoogle Scholar

  • 39 Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B [see comment]. Ann Neurol 2004;55:306–19. Crossref Medline ISIGoogle Scholar

  • 40 Engler H, Forsberg A, Almkvist O, Blomquist G, Larsson E, Savitcheva I, et al. Two-year follow-up of amyloid deposition in patients with Alzheimer's disease [see comment]. Brain 2006;129:2856–66. Crossref Medline ISIGoogle Scholar

  • 41 Rowe CC, Ng S, Ackermann U, Gong SJ, Pike K, Savage G, et al. Imaging beta-amyloid burden in aging and dementia. Neurology 2007;68:1718–25. Crossref Medline ISIGoogle Scholar

  • 42 Kubota T, Ushijima Y, Yamada K, Okuyama C, Kizu O, Nishimura T. Diagnosis of Alzheimer's disease using brain perfusion SPECT and MR imaging: which modality achieves better diagnostic accuracy? Eur J Nucl Med Mol Imaging 2005;32:414–21. Crossref Medline ISIGoogle Scholar

  • 43 Ng S, Villemagne VL, Berlangieri S, Lee S-T, Cherk M, Gong SJ, et al. Visual assessment versus quantitative assessment of 11C-PIB PET and 18F-FDG PET for detection of Alzheimer's disease. J Nucl Med 2007;48:547–52. Crossref Medline ISIGoogle Scholar

  • 44 Kawachi T, Ishii K, Sakamoto S, Sasaki M, Mori T, Yamashita F, et al. Comparison of the diagnostic performance of FDG-PET and VBM-MRI in very mild Alzheimer's disease. Eur J Nucl Med Mol Imaging 2006;33:801–9. Crossref Medline ISIGoogle Scholar

  • 45 Ballard CG, Burton EJ, Barber R, Stephens S, Kenny RA, Kalaria RN, et al. NINDS AIREN neuroimaging criteria do not distinguish stroke patients with and without dementia. Neurology 2004;63:983–8. Crossref Medline ISIGoogle Scholar

  • 46 Price CC, Jefferson AL, Merino JG, Heilman KM, Libon DJ. Subcortical vascular dementia: integrating neuropsychological and neuroradiologic data. Neurology 2005;65:376–82. Crossref Medline ISIGoogle Scholar

  • 47 Firbank MJ, Minett T, O'Brien JT. Changes in DWI and MRS associated with white matter hyperintensities in elderly subjects. Neurology 2003;61:950–4. Crossref Medline ISIGoogle Scholar

  • 48 Whitwell JL, Jack CR, Jr., Senjem ML, Josephs KA. Patterns of atrophy in pathologically confirmed FTLD with and without motor neuron degeneration [see comment]. Neurology 2006;66:102–4. Crossref Medline ISIGoogle Scholar

  • 49 Colloby SJ, Williams ED, Burn DJ, Lloyd JJ, McKeith IG, O'Brien JT. Progression of dopaminergic degeneration in dementia with Lewy bodies and Parkinson's disease with and without dementia assessed using (123)I-FP-CIT SPECT. Eur J Nucl Med Mol Imaging 2005;32:1176–85. Crossref Medline ISIGoogle Scholar

  • 50 Lobotesis K, Fenwick JD, Phipps A, Ryman A, Swann A, Ballard C, et al. Occipital hypoperfusion on SPECT in dementia with Lewy bodies but not AD. Neurology 2001;56:643–9. Crossref Medline ISIGoogle Scholar

  • 51 O'Brien JT, Colloby S, Fenwick J, Williams ED, Firbank M, Burn D, et al. Dopamine transporter loss visualized with FP-CIT SPECT in the differential diagnosis of dementia with Lewy bodies. Arch Neurol 2004;61:919–25. Crossref MedlineGoogle Scholar

  • 52 McKeith I, O'Brien J, Walker Z, Tatsch K, Booij J, Darcourt J, et al. Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study [see comment]. Lancet Neurol 2007;6:305–13. Crossref Medline ISIGoogle Scholar

  • 53 Hanyu H, Shimizu S, Hirao K, Kanetaka H, Iwamoto T, Chikamori T, et al. Comparative value of brain perfusion SPECT and [(123)I]MIBG myocardial scintigraphy in distinguishing between dementia with Lewy bodies and Alzheimer's disease [see comment]. Eur J Nucl Med Mol Imaging 2006;33:248–53. Crossref Medline ISIGoogle Scholar

  • 54 Barnes J, Godbolt AK, Frost C, Boyes RG, Jones BF, Scahill RI, et al. Atrophy rates of the cingulate gyrus and hippocampus in AD and FTLD. Neurobiol Aging 2007;28:20–8. Crossref Medline ISIGoogle Scholar

  • 55 Galton CJ, Patterson K, Graham K, Lambon-Ralph MA, Williams G, Antoun N, et al. Differing patterns of temporal atrophy in Alzheimer's disease and semantic dementia [comment]. Neurology 2001;57:216–25. Crossref Medline ISIGoogle Scholar

  • 56 Coulthard E, Firbank M, English P, Welch J, Birchall D, O'Brien J, et al. Proton magnetic resonance spectroscopy in frontotemporal dementia. J Neurol 2006;253:861–8. Crossref Medline ISIGoogle Scholar

  • 57 Davies RR, Kipps CM, Mitchell J, Kril JJ, Halliday GM, Hodges JR. Progression in frontotemporal dementia: identifying a benign behavioral variant by magnetic resonance imaging. Arch Neurol 2006;63:1627–31. Crossref MedlineGoogle Scholar

  • 58 Du AT, Jahng GH, Hayasaka S, Kramer JH, Rosen HJ, Gorno-Tempini ML, et al. Hypoperfusion in frontotemporal dementia and Alzheimer disease by arterial spin labeling MRI. Neurology 2006;67:1215–20. Crossref Medline ISIGoogle Scholar

  • 59 McNeill R, Sare GM, Manoharan M, Testa HJ, Mann DMA, Neary D, et al. Accuracy of single-photon emission computed tomography in differentiating frontotemporal dementia from Alzheimer's disease. J Neurol Neurosurg Psychiatry 2007;78:350–5. Crossref Medline ISIGoogle Scholar

  • 60 Dubois B, Feldman H, Jacova C, DeKosky ST, Barberger-Gateau P, Cummings J, et al. Research criteria for the diagnosis of Alzheimer's disease: Revising the NINCDS-ADRDA CRITERIA – a position paper. Lancet Neurol 2007;6:734–46. Crossref Medline ISIGoogle Scholar

Volume 80, Issue special_issue_2December 2007
Pages: S69-S167

© The British Institute of Radiology


History

  • ReceivedJuly 03,2007
  • AcceptedDecember 06,2007
  • Published onlineMarch 05,2014

Metrics